AUS
NZ
UK
CA
USA
IND
Highlights:
- FDA Approval: RECELL GO Mini, designed for smaller wounds, enhances the functionality of the RECELL GO platform.
- Optimized Design: The cartridge minimizes resource use and waste, broadening accessibility for clinicians.
- Market Growth: Targeting trauma and burn centers, the RECELL GO Mini is expected to drive growth starting in Q1 2025.
AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH), a leading commercial-stage regenerative medicine company, has received U.S. Food and Drug Administration (FDA) approval for its premarket approval (PMA) supplement for the RECELL GO® Mini, a new disposable cartridge designed to treat smaller wounds. The RECELL GO Mini extends the functionality of the RECELL GO platform by addressing wounds up to 480 square centimeters, complementing the standard RECELL GO cartridge, which treats areas up to 1,920 square centimeters.
Addressing Critical Needs in Skin Restoration
The RECELL GO Mini is specifically designed for smaller full-thickness skin defects, a significant and often underserved market segment. Utilizing the same multi-use processing device as the standard cartridge, the RECELL GO Mini optimizes resource use, reduces waste, and provides a streamlined solution for treating smaller wounds.
The smaller cartridge serves as an accessible entry point for clinicians who may not have previously used the RECELL GO system for smaller wounds, enabling its adoption in trauma and burn centers. By targeting this high-volume wound segment, the RECELL GO Mini broadens the platform’s clinical applications while enhancing patient care.
CEO Commentary
Jim Corbett, Chief Executive Officer of AVITA Medical, highlighted the significance of the approval, stating:
"The FDA approval of RECELL GO Mini strengthens our ability to provide clinicians with fit-for-purpose solutions that meet the diverse needs of patients with full-thickness wounds. This addition to the RECELL GO platform enhances our ability to drive better outcomes and expand access to innovative wound care solutions."
Strategic Rollout and Market Impact
AVITA Medical plans to launch the RECELL GO Mini in the first quarter of 2025, initially targeting trauma and burn centers that commonly treat smaller wounds. The company views the RECELL GO Mini as a strategic growth driver for the broader RECELL GO platform, aligning with its mission to expand its impact on patient care.
The RECELL GO Mini’s PMA supplement approval builds on the foundation of the original PMA for the RECELL Autologous Cell Harvesting Device and subsequent enhancements through additional PMA supplements.
Market Reaction
Following the announcement, AVITA Medical shares gained 6.30%, trading at AU$4.05 per share during morning trading hours on 24 December 2024.
